Noncutaneous Melanomas: A Single-Center Analysis

Dermatology

Volumn 232, Issue 1, 2016, Pages 22-29

  Del Prete, Valerio ^a   Chaloupka, Karla ^a   Holzmann, David ^a   Fink, Daniel ^a   Levesque, Mitchell ^a   Dummer, Reinhard ^a   Goldinger, Simone M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Mucosal melanoma; Noncutaneous melanoma; Ocular melanoma; Sinonasal melanoma; Uveal melanoma; Vulvovaginal melanoma

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BINIMETINIB; BORTEZOMIB; CARBOPLATIN; CHIR 265; CISPLATIN; DACARBAZINE; DOXORUBICIN; IMATINIB; IPILIMUMAB; LOMUSTINE; NILOTINIB; PACLITAXEL; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; RAS PROTEIN; SELUMETINIB; SONIDEGIB; SORAFENIB; STEM CELL FACTOR; TAUROLIDINE; TEMOZOLOMIDE; VINDESINE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE CONTROL; EYE MELANOMA; FEMALE; GENE MUTATION; HUMAN; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINONASAL MELANOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VULVOVAGINAL MELANOMA; EYE NEOPLASMS; GENETICS; GENITAL NEOPLASMS, FEMALE; MALE; MIDDLE AGED; MUTATION; NOSE NEOPLASMS; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; EYE NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NOSE NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES;

EID: 84958113994     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000441444     Document Type: Article

References (49)

1. McLaughlin CC, et al: Incidence of noncutaneous melanomas in the US. Cancer 2005; 103: 1000-1007.
2. Bishop KD, Olszewski AJ: Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis. Int J Cancer 2014; 134: 2961-2971.
3. Lund VJ, et al: Sinonasal malignant melanoma: an analysis of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. Rhinology 2012; 50: 203-210.
4. Krengli M, et al: What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol 2008; 65: 121-128.
5. Stanimirov Rossi O, et al: Multilocular sinonasal malignant melanoma: A poor prognostic subgroup? Eur Arch Otorhinolaryngol 2015; 272: 123-129.
6. Puusaari I, et al: Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology 2003; 110: 2223-2234.
7. Hawkins BS: Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials 2011; 8: 661-673.
8. Caujolle JP, et al: Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. Int J Radiat Oncol Biol Phys 2013; 85: 1218-1224.
9. Prescher G, et al: Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225.
10. Damato B, et al: Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011; 30: 285-295.
11. Egger E, et al: Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001; 51: 138-147.
12. Damato B, et al: Local tumor control after 106 Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 385-391.
13. Shields CL, et al: Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011; 118: 389-395.
14. Shields CL, et al: Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 2000; 118: 1497-1507.
15. Damato B, Coupland SE: Management of conjunctival melanoma. Expert Rev Anticancer Ther 2009; 9: 1227-1239.
16. Curtin JA, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
17. Satzger I, et al: Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008: 99: 2065-2069.
18. Handolias D, et al: Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102: 1219-1223.
19. Omholt K, et al: KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17: 3933-3942.
20. Papaspyrou G, et al: Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-KIT inhibitors. Melanoma Res 2011; 21: 475-482.
21. Schoenewolf NL, et al: Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012; 48: 1842-1852.
22. Zebary A, et al: KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: A study of 56 cases. Br J Cancer 2013; 109: 559-564.
23. Henriquez F, et al: The T1799A BRAF mutation is present in iris melanoma. Invest Ophthalmol Vis Sci 2007; 48: 4897-4900.
24. Gear H, et al: BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci 2004; 45: 2484-2488.
25. Griewank KG, et al: Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013; 19: 3143-3152.
26. Spendlove HE, et al: BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res 2004; 14: 449-452.
27. Cohen Y, et al: Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 2876-2878.
28. Beadling C, et al: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-6828.
29. Sagoo MS, et al: Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene 2014; 33: 4722-4723.
30. Shields CL, et al: Prognosis of uveal melanoma in 500 cases using genetic testing of fineneedle aspiration biopsy specimens. Ophthalmology 2011; 118: 396-401.
31. Damato B, et al: Cytogenetics of uveal melanoma: A 7-year clinical experience. Ophthalmology 2007; 114: 1925-1931.
32. Collaborative Ocular Melanoma Study Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report No 15. Arch Ophthalmol 2001; 119: 670-676.
33. Damato BE, Coupland SE: Ocular melanoma. Saudi J Ophthalmol 2012; 26: 137-144.
34. Del Vecchio M, et al: Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014; 50: 121-127.
35. Postow MA, et al: Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013; 18: 726-732.
36. Luke JJ, et al: Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013; 119: 3687-3695.
37. Maio M, et al: Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24: 2911-2915.
38. Zimmer L, et al: Phase II DeCOG study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One 2015; 10:e0118564.
39. Wolchok JD, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
40. Hamid O, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
41. Hodi FS, et al: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31: 3182-3190.
42. Schoenewolf NL, Urosevic-Maiwald M, Dummer R: Tumour heterogeneity of mucosal melanomas during treatment with imatinib. Br J Dermatol 2011; 165: 419-424.
43. Takayama N, et al: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002; 119: 106-108.
44. Hughes B, et al: Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer 2004; 4: 74.
45. Zukotynski K, et al: Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging 2014; 14: 30.
46. Guo J, et al: Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909.
47. Belloni B, et al: Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012; 97: 191-202.
48. Carvajal RD, et al: Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial. JAMA 2014; 311: 2397-2405.
49. Eggermont AM, et al: Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.